Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) price closed lower on current market day and dropping -2.34% below its previous close.
A look at the daily price movement shows that the last close reads $14.93, with intraday deals fluctuated between $13.97 and $17.25. The company’s 5Y monthly beta was ticking 1.449. Taking into account the 52-week price action we note that the stock hit a 52-week high of $15.25 and 52-week low of $5.15. The stock added 32.07% on its value in the past month.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Centessa Pharmaceuticals plc ADR, which has a market valuation of $1.65 billion, is expected to release its quarterly earnings report in October.
Technical indicators in stocks provide crucial insights into market trends, guiding investors with precise entry and exit points based on price movements for informed decision-making.On the technical perspective front, indicators give CNTA a short term outlook of 100% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Buy, while an average of long term indicators are currently assigning the stock as 100% Buy.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 6 analysts have assigned CNTA a recommendation rating as follows: 3 rate it as a Hold; 3 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Centessa Pharmaceuticals plc ADR (CNTA) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that CNTA’s price is at present 11.84% off the SMA20 and 30.68% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 66.71, with weekly volatility standing at 11.00%. The indicator jumps to 8.10% when calculated based on the past 30 days. Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA)’s beta value is holding at 1.38, while the average true range (ATR) indicator is currently reading 1.04. Considering analysts have assigned the stock a price target range of $20-$20 as the low and high respectively, we find the trailing 12-month average consensus price target to be $20. Based on this estimate, we see that current price is roughly -37.17% off the estimated low and -37.17% off the forecast high. Investors will no doubt be excited to see the share price fall to $20, which is the median consensus price, and at that level CNTA would be -37.17% from current price.
An analysis of the Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) stock in terms of its daily trading volume indicates that the 3-month average is 333.92K. However, this figure increases on the past 10-day timeline to an average of 0.89 million.
Current records show that the company has 98.77M in outstanding shares. The insiders’ percentage holdings are 33.36% of outstanding shares while the percentage share held by institutions stands at 43.30%. The stats also highlight that short interest as of 2024-08-15, stood at 1.1 million shares, which puts the short ratio at the time at 3.35. From this we can glean that short interest is 124.00 of company’s current outstanding shares. Notably, we see that shares short in August fall slightly given the previous month’s figure stood at 1.45 million. But the 83.17% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
